2024
Cost trends of Metastatic Renal Cell Carcinoma Therapy: the impact of oral anticancer agents and immunotherapy
Forman R, Long J, Westvold S, Agnish K, McManus H, Leapman M, Hurwitz M, Spees L, Wheeler S, Gross C, Dinan M. Cost trends of Metastatic Renal Cell Carcinoma Therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectrum 2024, pkae067. PMID: 39133171, DOI: 10.1093/jncics/pkae067.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsOAA useAssociated with decreased adherenceRenal cell carcinomaAnticancer agentsDays of treatmentCombination therapyCell carcinomaStudy patientsInitial treatmentReal-world costsCombination groupImmunotherapyPatientsOOP costsTherapyTreatment typePercent daysPerspective of payersTreatmentClaims dataMedicare patientsAnalyzed differencesFee-for-service MedicareCharacterization of time toxicity in older patients with metastatic breast cancer
Atre S, Soulos P, Kuderer N, Gross C, Baum L, Dinan M, Lustberg M. Characterization of time toxicity in older patients with metastatic breast cancer. Breast Cancer Research And Treatment 2024, 1-10. PMID: 38816556, DOI: 10.1007/s10549-024-07379-7.Peer-Reviewed Original ResearchMetastatic breast cancerBone-modifying agentsComorbid medical conditionsOlder patientsBreast cancerRetrospective cohort studySEER-Medicare databaseTreatment typeCancer treatment modalityTreatment modalitiesSEER-MedicareCohort studyUnadjusted analysisPatientsAge-related impactCancer treatmentComorbiditiesDay patientsCancerRadiotherapyOlder ageMedical conditionsToxicityTreatmentSociodemographic factors
2023
Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.
Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsInitial treatmentRetrospective cohort studyUse of immunotherapyYear of diagnosisRenal cell carcinomaDirect treatment costsMean Medicare paymentsMedicare paymentsMedicare Part DInitial therapyCohort studyMetastatic diagnosisCell carcinomaCombination therapyImmunotherapyMedicare beneficiariesPatientsAge 65Disease controlOlder ageStudy periodTherapyDiagnosisCharacteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancer
Check D, Jackson B, Reeder-Hayes K, Dinan M, Faherty E, Kwong J, Mehta S, Spees L, Wheeler S, Wilson L, Lam C. Characteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancer. Breast Cancer Research And Treatment 2023, 203: 329-338. PMID: 37875669, DOI: 10.1007/s10549-023-07142-4.Peer-Reviewed Original ResearchConceptsHER2-low breast cancerBreast cancerHealthcare utilizationOutcomes of patientsRetrospective cohort studyStage IV diseaseStage IV patientsMetastatic breast cancerNew treatment guidelinesRate of hospitalizationBreast cancer patientsClinical characteristicsCohort studyHazard ratioIV patientsOverall cohortPositive diseaseTreatment guidelinesIHC 0Utilization outcomesTreatment optionsCancer patientsSurvival differencesPatientsStage IVTrends in new and persistent opioid use in older adults with and without cancer
Baum L, KC M, Soulos P, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Trends in new and persistent opioid use in older adults with and without cancer. Journal Of The National Cancer Institute 2023, 116: 316-323. PMID: 37802882, DOI: 10.1093/jnci/djad206.Peer-Reviewed Original ResearchAdditional opioid useNew opioid useOpioid useNon-metastatic cancerPersistent opioid useRetrospective cohort studySolid tumor malignanciesClinical strataEligible patientsNaïve patientsOpioid prescribingMetastatic patientsSurgery patientsCohort studySEER-MedicareMetastatic cancerPatientsTumor malignancyCancerOlder adultsSurgeryRandom sampleAdditional useChemotherapyPrescribingDisparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma
Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum 2023, 7: pkad036. PMID: 37202354, PMCID: PMC10276895, DOI: 10.1093/jncics/pkad036.Peer-Reviewed Original ResearchConceptsOral anticancer agentsTherapy utilizationMedicare beneficiariesNon-Hispanic white raceMetastatic renal cell carcinomaNon-Hispanic black raceOlder US patientsUS Medicare beneficiariesRenal cell carcinomaLogistic regression modelsTherapy receiptMultivariable adjustmentSystemic therapyMale sexUS patientsCell carcinomaStudy criteriaBlack raceFemale sexPatient raceWhite raceImmunotherapyOutcomes persistSexPatients
2022
Genetic testing in privately insured women with surgically treated breast cancer
Dinan M, Pitafi S, Greenup R, Long J, Gross C. Genetic testing in privately insured women with surgically treated breast cancer. Breast Cancer Research And Treatment 2022, 198: 177-181. PMID: 36542252, DOI: 10.1007/s10549-022-06829-4.Peer-Reviewed Original ResearchConceptsBreast cancerGenetic testingRoutine breast cancer careBRCA1/BRCA2 genetic testingHormone receptor statusBreast cancer careInvasive breast cancerBRCA2 genetic testingReceptor statusWomen 50Cancer careAge 45Family historyOlder womenInsurer databaseYoung womenCancerWomenCoverage policiesUnclear implicationsPatientsSurgeryPurposeRatesYearsPrevalenceConcurrent prescribing of opioids with other sedating medications after cancer diagnosis: a population-level analysis
Check D, Baggett C, Kim K, Merlin J, Oeffinger K, Winn A, Roberts M, Robinson T, Dinan M. Concurrent prescribing of opioids with other sedating medications after cancer diagnosis: a population-level analysis. Supportive Care In Cancer 2022, 30: 9781-9791. PMID: 36396793, DOI: 10.1007/s00520-022-07439-y.Peer-Reviewed Original ResearchConceptsConcurrent prescribingSedating medicationsPatient characteristicsMedication-related eventsRetrospective cohort studyNon-metastatic cancerPopulation-based assessmentCancer registry dataMental health conditionsSubstance use disordersPrivate insurance claimsConcurrent prescriptionsCohort studyHispanic patientsSymptom managementRelative riskRegistry dataGabapentinoidsOpioidsPrescribingUse disordersPatientsPoisson regressionPrior useMedicationsHealth Services Research
Dinan M, Check D. Health Services Research. 2022, 1-13. DOI: 10.1002/9781119000822.hfcm051.pub2.ChaptersOral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC)
Dinan MA, Wilson LE, Greiner MA, Spees LP, Pritchard JE, Zhang T, Kaye D, George D, Scales CD, Baggett CD, Gross CP, Leapman MS, Wheeler SB. Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC). Urology 2022, 168: 129-136. PMID: 35878815, PMCID: PMC9588695, DOI: 10.1016/j.urology.2022.07.012.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaOral anticancer agentsRenal cell carcinomaCell carcinomaMedicare beneficiariesPocket costsOdds of adherenceRetrospective cohort studyDisease-specific survivalReal-world adherenceRCC-specific survivalProportion of daysNon-significant trendAdherent useOAA therapyCohort studyElderly patientsMultivariable analysisStudy criteriaUnivariate analysisOAA treatmentPatientsCarcinomaAdherenceSurvivalAssociation between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma
Pritchard JE, Wilson LE, Miller SM, Greiner MA, Cohen HJ, Kaye DR, Zhang T, Dinan MA. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma. Journal Of The American Geriatrics Society 2022, 70: 2330-2343. PMID: 35499667, PMCID: PMC9378524, DOI: 10.1111/jgs.17826.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaOral anticancer agentsRenal cell carcinomaMRCC diagnosisCognitive impairmentCell carcinomaFive-year survival rateSEER-Medicare patientsMedicare Part D coveragePart D coverageMild cognitive impairmentMRCC patientsMRCC treatmentEligible patientsOlder patientsTreatment initiationKidney cancerAgent useOAA treatmentPatientsStage IVSurvival rateNew casesDiagnosisD diagnosisEvaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma
Miller SM, Wilson LE, Greiner MA, Pritchard JE, Zhang T, Kaye DR, Cohen HJ, Becher RD, Maerz LL, Dinan MA. Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma. Journal Of Geriatric Oncology 2022, 13: 635-643. PMID: 34996724, PMCID: PMC9232862, DOI: 10.1016/j.jgo.2021.12.012.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaNon-cancer controlsRenal cell carcinomaMRCC diagnosisMild cognitive impairmentCell carcinomaRisk factorsCognitive impairmentOlder adultsProportional hazards modelNew cancer treatmentsCohort entryOlder patientsSurgical therapyMAIN OUTCOMEExclusion criteriaAgent useDisease processHazards modelPatientsMedicare datasetCancer treatmentDiagnosisDementiaCarcinoma
2021
Vitamin D, Insulin-Like Growth Factor, and Cognitive Performance: Age and Sex Variations
Miller S, Wilson L, Greiner M, Pritchard J, Zhang T, Kaye D, Cohen H, Dinan M. Vitamin D, Insulin-Like Growth Factor, and Cognitive Performance: Age and Sex Variations. Innovation In Aging 2021, 5: 703-703. PMCID: PMC8969788, DOI: 10.1093/geroni/igab046.2613.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRenal cell carcinomaProportional hazards regressionOral anticancer agentsMRCC diagnosisCell carcinomaHazards regressionRisk factorsCox proportional hazards regressionOlder adultsNon-cancer controlsMild cognitive impairmentCohort entryRenal dysfunctionOnly patientsSurgical therapyWhite patientsBlack patientsSEER-MedicareDementia onsetMAIN OUTCOMEExclusion criteriaHigh riskPatientsCognitive impairmentAdoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management
Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open 2021, 4: e2128646. PMID: 34623406, PMCID: PMC8501394, DOI: 10.1001/jamanetworkopen.2021.28646.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingHospital referral regionsProportion of patientsProstate cancerGenomic testingCohort studyReferral regionsRetrospective cohort studyProstate cancer carePatient-level analysisCommercial insurance claimsProstate cancer managementUS hospital referral regionsYears of ageProportion of menPatients 40Definitive treatmentCancer careTesting uptakeHRR levelMAIN OUTCOMECancer managementPatientsRegional uptakeProvider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma
Spees LP, Wheeler SB, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales CD, Pritchard JE, Leapman M, Gross CP, Dinan MA. Provider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Cancer Medicine 2021, 10: 6653-6665. PMID: 34480518, PMCID: PMC8495289, DOI: 10.1002/cam4.4201.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaPatient-level factorsRenal cell carcinomaCell carcinomaRisk ratioState cancer registry dataPatient-level predictorsPatient-level characteristicsCancer registry dataProvider Enumeration SystemMRCC diagnosisMedical oncologyInsurance typeMedicare patientsRegistry dataFemale providersPatientsMedian proportionPoisson regressionCare issuesPrivate insuranceMale providersAdherenceCarcinomaAnticancer agentsReal-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States
Wilson LE, Spees L, Pritchard J, Greiner MA, Scales CD, Baggett CD, Kaye D, George DJ, Zhang T, Wheeler SB, Dinan MA. Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States. Kidney Cancer 2021, 5: 115-127. PMID: 34632169, PMCID: PMC8474520, DOI: 10.3233/kca-210119.Peer-Reviewed Original ResearchOral anticancer agentsMetastatic RCCPatient characteristicsMetastatic renal cell carcinomaPocket costsFirst oral therapySEER-Medicare analysisRepresentative patient populationRenal cell carcinomaAnticancer agentsPrescription drug coverageRace/ethnicityMRCC diagnosisMost patientsOral therapyUnmarried patientsCell carcinomaPatient populationAdvanced ageInclusion criteriaPatientsDrug coverageAge 65Medicare Part D prescription drug coverageSocioeconomic disparitiesPatterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma
Wheeler SB, Spees LP, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales CD, Pritchard JE, Dinan MA. Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma. JCO Oncology Practice 2021, 17: e1895-e1904. PMID: 34138665, PMCID: PMC8678030, DOI: 10.1200/op.20.01082.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaOral anticancer agentsRenal cell carcinomaIndex dateCell carcinomaRisk ratioPatterns of usePatients age 80Patients age 18Population-based studyAdjusted risk differenceOral therapyPatient characteristicsContinuous enrollmentHigh frailtyAge 80Agent useRisk differencePatientsDiverse patientsComorbiditiesAge 18Regulatory approvalCarcinomaLog-Poisson modelMediators of racial disparity in the use of prostate MRI.
Leapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. Mediators of racial disparity in the use of prostate MRI. Journal Of Clinical Oncology 2021, 39: 6554-6554. DOI: 10.1200/jco.2021.39.15_suppl.6554.Peer-Reviewed Original ResearchProstate cancerRacial disparitiesProstate MRIMRI useArea-level measuresObserved racial disparitiesEligible patientsPathologic factorsDual eligibilityWhite patientsBlack patientsSEER regionMedicare databaseCancer careSix-month periodPatientsSociodemographic factorsCancerMRIZip codesOlder AmericansMediatorsDiagnostic toolObserved disparitiesHigh-poverty areasReporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics
Varma T, Wallach JD, Miller JE, Schnabel D, Skydel JJ, Zhang AD, Dinan MA, Ross JS, Gross CP. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. JAMA Network Open 2021, 4: e217063. PMID: 33877309, PMCID: PMC8058642, DOI: 10.1001/jamanetworkopen.2021.7063.Peer-Reviewed Original ResearchConceptsNovel cancer therapeuticsPostmarketing studyBlack patientsCancer therapeuticsDemographic dataOlder adultsUS cancer populationUS Cancer StatisticsCross-sectional studyRace/ethnicityParticipants' demographic characteristicsPercentage of trialsPatient sexCancer populationClinical studiesCancer statisticsMAIN OUTCOMEDrug AdministrationFDA approvalStudy participantsCancer typesDemographic characteristicsDemographic informationStudy samplePatientsPatterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients.
Wheeler S, Spees L, Jackson B, Baggett C, Wilson L, Greiner M, George D, Scales C, Pritchard J, Dinan M. Patterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients. Journal Of Clinical Oncology 2021, 39: 279-279. DOI: 10.1200/jco.2021.39.6_suppl.279.Peer-Reviewed Original ResearchMetastatic renal cell carcinoma patientsRenal cell carcinoma patientsCell carcinoma patientsOral anti-cancer agentsCarcinoma patientsRisk ratioPatterns of useRisk differenceGreater comorbidity burdenMetastatic RCC patientsPopulation-based studyPatient-level characteristicsMonths of preAdjusted risk differencePoor quality careComorbidity burdenIndex dateAnti-cancer agentsMetastatic RCCPatient characteristicsContinuous enrollmentRCC patientsTreatment advancesType of insurancePatients